Recently, type 2 diabetes treatment has focused on agents belonging to two newfound anti-diabetes classes, namely sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists, because of their impressive benefits in reducing the risk of CV events and heart failure [26]. The gene discussed is GCG; the disease is diabetes mellitus.